BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 9/20/2026

1. SPY
2. XENE
3. HUBS
4. NUE
5. ONON
6. AAPL
7. RTB
8. AZN
9. SPCX
10. TRMD

Go back to BioVie Announces Topline Results of Phase 2 SUNRISE-PD Trial of Bezisterim in Early Parkinson’s Disease
(NASDAQ: BIVI) Delayed: 1.61 -0.17 (9.55%)
Previous Close $1.78    52 Week High $0.40 
Open $1.78    52 Week Low $0.17 
Day High $1.84    P/E N/A 
Day Low $1.61    EPS $0.00 
Volume 406,240